Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study Abstract #1284

Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.
Aim(s): To evaluate PK of LD SQ vs IM.
Materials and methods: In a phase I study, healthy adult volunteers received 1 mg LD (IV bolus) followed by 60 mg 0.246 mg/mg deep SC or IM. Serial blood samples were analyzed.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials
Introduction: LAN provide antitumor effects and symptom control in NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Nuria Buil-Bruna
Keywords: PK, dosing
#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Diane Reidy-Lagunes
Keywords: Lung NETs, lanreotide
#1338 Use of Lanreotide LAR in the Case of Intolerance of Octreotide LAR in Patients Well-differentiated NETs
Introduction: Intolerance of Octreotide is about 10 % of cases
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs
Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Keywords: Lung NETs, lanreotide
#1185 Lanreotide Autogel (LAN) 120 mg in Patients with Progressive Enteropancreatic (EP-) NETs: Data from the CLARINET Open-Label Extension (OLE) Study
Introduction: In the CLARINET core study, LAN 120 mg significantly prolonged PFS vs placebo (PBO) in metastatic grade 1 or 2 EP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin